32
Participants
Start Date
December 16, 2013
Primary Completion Date
November 4, 2014
Study Completion Date
November 4, 2014
somapacitan
"A single dose administered subcutaneously (s.c., under the skin) of 4 different doses of NNC0195-0092 in an escalating order.~Each subject will be allocated to one dose level only. After completion of each dose cohort, a safety evaluation will be conducted prior to dose escalation."
somatropin
Administered subcutaneously (s.c., under the skin) once daily for 7 days. The daily dose is 0.03 mg/kg/day.
Novo Nordisk Investigational Site, Skopje
Novo Nordisk Investigational Site, Brussels
Novo Nordisk Investigational Site, Brussels
Novo Nordisk Investigational Site, Geneva
Novo Nordisk Investigational Site, Ljubljana
Novo Nordisk Investigational Site, Linz
Novo Nordisk Investigational Site, Basel
Novo Nordisk Investigational Site, Bergen
Novo Nordisk Investigational Site, Graz
Novo Nordisk Investigational Site, Santiago de Compostela
Novo Nordisk Investigational Site, Toulouse
Novo Nordisk Investigational Site, Haifa
Novo Nordisk Investigational Site, Kfar Saba
Novo Nordisk Investigational Site, Petah Tikva
Novo Nordisk Investigational Site, Tel Litwinsky
Novo Nordisk Investigational Site, Paris
Novo Nordisk Investigational Site, Jerusalem
Novo Nordisk Investigational Site, Vienna
Novo Nordisk Investigational Site, Barcelona
Novo Nordisk Investigational Site, Esplugues Llobregat(Barcelona)
Novo Nordisk Investigational Site, Vitoria-Gasteiz
Novo Nordisk Investigational Site, Stockholm
Lead Sponsor
Novo Nordisk A/S
INDUSTRY